Myriad Genetics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Myriad Genetics Stock Forecast and Price Target
If the average price target of $25.00 set by eight distinguished experts for Myriad Genetics over the past few weeks is reached this year, there would be a potential upside of approximately 30.07% from the last closing price in May, 2024. This potential increase is based on a high estimate of $31.00 and a low estimate of $17.00. If you're not interested in MYGN stock, you may be interested in its competitors.
30.07% Upside
Myriad Genetics Fair Value Forecast for 2023 - 2025 - 2030
Myriad Genetics's Price has grown in the last four years, jumping from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will reach $20.64 – an increase of 100.00%. For the next eight years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$105.92 | Buy/Sell | $118.92 | 18.01% |
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$123.99 | Buy/Sell | $159.28 | 20.98% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.91 | Buy/Sell | $81.06 | 11.32% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$200.25 | Buy/Sell | $241.28 | 20.85% |
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$136.34 | Buy/Sell | $141.17 | 6.35% |
Myriad Genetics Revenue Forecast for 2023 - 2025 - 2030
Myriad Genetics's Revenue has grown in the last three years, jumping from $599.60M to $753.20M – an increase of 25.62%. In the next year, analysts predict that Revenue will reach $819.14M – an increase of 8.75%. For the next eight years, the forecast is for Revenue to grow by 36.16%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| WMS Stock Forecast | Advanced Drainage Systems | Buy |
15
|
$161.94 | Buy/Sell | $144.13 | 13.31% |
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
56.50€ | Buy/Sell | 0.00€ | 6.19% |
| TECH Stock Forecast | Bio-Techne Corp | Buy |
16
|
$75.60 | Buy/Sell | $100.78 | 9.13% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NTRA Stock Forecast | Natera | Outperform |
7
|
$93.72 | Buy/Sell | $74.41 | 10.44% |
| EXAS Stock Forecast | Exact Sciences | Buy |
8
|
$60.54 | Buy/Sell | $90.32 | 47.36% |
| QGEN Stock Forecast | QIAGEN N.V. | Outperform |
15
|
$42.68 | Buy/Sell | $0.00 | 17.15% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SHL Stock Forecast | Sonic Healthcare | Hold |
18
|
$25.94 | Buy/Sell | $34.12 | 19.51% |
| BIO Stock Forecast | Bio-Rad Laboratories Inc | Buy |
16
|
$279.31 | Buy/Sell | $536.80 | 50.37% |
| TXG Stock Forecast | 10x Genomics | Outperform |
6
|
$26.29 | Buy/Sell | $58.14 | 54.05% |
Myriad Genetics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Myriad Genetics's EBITDA has decreased from $-97.00M to $-82.20M – a 15.26% drop. For the following year, the 3 analysts predict that Myriad Genetics's EBITDA will drop by 138.77%, reaching $31.87M. In 2030, the professionals' prediction is that MYGN's EBITDA will decrease by 172.43%, reaching $59.54M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TNE Stock Forecast | Technology One | Hold |
16
|
$16.05 | Buy/Sell | $16.29 | 2.80% |
| GH Stock Forecast | Guardant Health | Buy |
6
|
$18.58 | Buy/Sell | $43.00 | 136.81% |
| 300676 Stock Forecast | BGI Genomics | - |
17
|
¥41.13 | Buy/Sell | ¥0.00 | -100.00% |
Myriad Genetics EBIT Forecast for 2023 - 2025 - 2030
Myriad Genetics's EBIT has decreased by 14.23% In the last three years, from $-168.60M to $-144.60M. In the following year, the 5 analysts surveyed believe that Myriad Genetics's EBIT will decrease by 108.46%, reaching $12.23M. According to professionals, by 2030, Myriad Genetics's EBIT will have decreased by 159.02%, falling down to $85.35M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SDGR Stock Forecast | Schrödinger | Outperform |
6
|
$23.19 | Buy/Sell | $44.22 | 57.40% |
| TWST Stock Forecast | Twist Bioscience | Outperform |
4
|
$32.01 | Buy/Sell | $34.00 | 29.65% |
| NEO Stock Forecast | NeoGenomics | Outperform |
8
|
$14.72 | Buy/Sell | $20.09 | 29.08% |
Myriad Genetics EPS Price Prediction Forecast for 2023 - 2025 - 2030
Myriad Genetics's EPS has grown in the last four years, jumping from $-0.66 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will reach $0.05 – an increase of 100.00%. For the next eight years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VCYT Stock Forecast | Veracyte | Outperform |
11
|
$20.19 | Buy/Sell | $32.17 | 60.97% |
| OPK Stock Forecast | OPKO Health | Outperform |
8
|
$1.01 | Buy/Sell | $6.70 | 296.04% |
| FLGT Stock Forecast | Fulgent Genetics | Hold |
16
|
$21.24 | Buy/Sell | $31.50 | 17.70% |
.jpg)